[7] Kakihana W, Akai M, Nakazawa K, Takashima T, Naito K, Torii S. Effects of laterally wedged insoles on knee and subtalar joint moments. Arch Phys Med Rehabil 2005;86:1465–71.

[8] Shimada S, Kobayashi S, Wada M, Uchida K, Sasaki S, Kawahara H, et al. Effects of disease severity on response to lateral wedged shoe insole for medial compartment knee osteoarthritis. Arch Phys Med Rehabil 2006;87:1436–41.

[9] Brouwer RW, Jakma TS, Verhagen AP, Verhaar JA, Bierma-Zeinstra SM. Braces and orthoses for treating osteoarthritis of the knee. Cochrane Database Syst Rev 2005;CD004020.

[10] Krohn K. Footwear alterations and bracing as treatments for knee osteoarthritis. Curr Opin Rheumatol 2005;17:653–6.

[11] Sasaki T, Yasuda K. Clinical evaluation of the treatment of osteoarthritic knees using a newly designed wedged insole. Clin Orthop Relat Res 1987;221:181–7.

[12] Keating EM, Faris PM, Ritter MA, Kane J. Use of lateral heel and sole wedges in the treatment of medial osteoarthritis of the knee. Orthop Rev 1993;22:921–4.

[13] Maillefert JF, Hudry C, Baron G, Kieffert P, Bourgeois P, Lechevalier D, et al. Laterally wedged insoles in the treatment of medial knee osteoarthritis: a prospective randomized controlled study. Osteoarthritis Cartilage 2001;9:738–45.

[14] Pham T, Maillefert JF, Hudry C, Kieffert P, Bourgeois P, Lechevalier D, et al. Laterally elevated wedged insoles in the treatment of medial knee osteoarthritis: a two-year prospective randomized controlled study. Osteoarthritis Cartilage 2004;12:46–55.

[15] Baker K, Goggins J, Xie H, Szumowski K, LaValley M, Hunter DJ, et al. A randomized crossover trial of a wedged insole for treatment of knee osteoarthritis. Arthritis Rheum 2007;56:1198–203.

[16] Fisher DS, Dyrby CO, Mundermann A, Morag E, Andriacchi TP. In healthy subjects without knee osteoarthritis, the peak knee adduction moment influences the acute effect of shoe interventions designed to reduce medial compartment knee load. J Orthop Res 2007;25:540–6.

[17] Andriacchi TP, Mundermann A. The role of ambulatory mechanics in the initiation and progression of knee osteoarthritis. Curr Opin Rheumatol 2006;18:514–8.

[18] Hiraoka H, Nakajima K, Oda H. Non-surgical treatments for gonarthrosis. Clin Calcium 2002;12:92–7.

[19] Atman D. Practical statistics for medical research. London: Chapman & Hall; 1991.

[20] Kakihana W, Akai M, Yamasaki N, Takashima T, Nakazawa K. Changes of joint moments in the gait of normal subjects wearing laterally wedged insoles. Am J Phys Med Rehabil 2004;83:273–8.

[21] Kakihana W, Torii S, Akai M, Nakazawa K, Fukano M, Naito K. Effect of a lateral wedge on joint moments during gait in subjects with recurrent ankle sprain. Am J Phys Med Rehabil 2005;84:858–64.

[22] Nester CJ, van der Linden ML, Bowker P. Effect of foot orthoses on the kinematics and kinetics of normal walking gait. Gait Posture 2003;17:180–7.

[23] Teichtahl AJ, Wluka AE, Morris ME, Davis SR, Cicuttini FM. The relationship between the knee adduction moment and knee pain in middle-aged women without radiographic osteoarthritis. J Rheumatol 2006;33:1845–8.

[24] Thorp LE, Sumner DR, Block JA, Moisio KC, Shott S, Wimmer MA. Knee joint loading differs in individuals with mild compared with moderate medial knee osteoarthritis. Arthritis Rheum 2006;54:3842–9.

[25] Hunt MA, Birmingham TB, Giffin JR, Jenkyn TR. Associations among knee adduction moment, frontal plane ground reaction force, and lever arm during walking in patients with knee osteoarthritis. J Biomech 2006;39: 2213–20.

[26] Rosenbaum D, Rodl R, Entrup M, Klein D. Shoe modification or inserts can effect relief of the knee joint. Z Orthop Ihre Grenzgeb 2002;140:579–80.

[27] Andrews M, Noyes FR, Hewett TE, Andriacchi TP. Lower limb alignment and foot angle are related to stance phase knee adduction in normal subjects: a critical analysis of the reliability of gait analysis data. J Orthop Res 1996;14:289–95.

[28] Hurwitz DE, Ryals AB, Case JP, Block JA, Andriacchi TP. The knee adduction moment during gait in subjects with knee osteoarthritis is more closely correlated with static alignment than radiographic disease severity, toe out angle and pain. J Orthop Res 2002;20:101–7.

[29] Chang A, Hurwitz D, Dunlop D, Song J, Cahue S, Hayes K, et al. The relationship between toe-out angle during gait and progression of medial tibiofemoral osteoarthritis. Ann Rheum Dis 2007;66:1271–5.

[30] Yasuda K, Sasaki T. The mechanics of treatment of the osteoarthritic knee with a wedged insole. Clin Orthop Relat Res 1987;215:162–72.

The interaction of monocytes with rheumatoid synovial cells is a key step in LIGHT-mediated inflammatory bone destruction

Satoru Ishida,[1,2] Shoji Yamane,[1,2]
Saori Nakano,[1] Toru Yanagimoto,[2]
Yukie Hanamoto,[1] Miki Maeda-
Tanimura,[2] Tomoko Toyosaki-
Maeda,[2] Jun Ishizaki,[2] Yoshiyuki
Matsuo,[2] Naoshi Fukui,[1] Tsunetoshi
Itoh,[3] Takahiro Ochi[1] and Ryuji
Suzuki[1]

[1]Clinical Research Center for Allergy and
Rheumatology, National Hospital Organiza-
tion, Sagamihara National Hospital, Sagami-
hara, Kanagawa, Japan, [2]Discovery Research
Laboratories, Shionogi & Co., Ltd., Toyonaka,
Osaka, Japan, and [3]Department of Immuno-
logy and Embryology, Tohoku University
School of Medicine, Aoba-ku, Sendai, Japan

Summary

Formation of osteoclasts and consequent joint destruction are hallmarks
of rheumatoid arthritis (RA). Here we show that LIGHT, a member of
the tumour necrosis factor (TNF) superfamily, induced the differentiation
into tartrate-resistant acid phosphatase (TRAP)-positive multinucleated
cells (MNCs) of CD14$^+$ monocytes cocultured with nurse-like cells iso-
lated from RA synovium, but not of freshly isolated CD14$^+$ monocytes.
Receptor activator of nuclear factor-κB ligand (RANKL) enhanced this
LIGHT-induced generation of TRAP-positive MNCs. The MNCs showed
the phenotypical and functional characteristics of osteoclasts; they showed
the expression of osteoclast markers such as cathepsin K, actin-ring for-
mation, and the ability to resorb bone. Moreover, the MNCs expressed
both matrix metalloproteinase 9 (MMP-9) and MMP-12, but the latter
was not expressed in osteoclasts induced from CD14$^+$ monocytes by
RANKL. Immunohistochemical analysis showed that the MMP-12-produc-
ing MNCs were present in the erosive areas of joints in RA, but not in
the affected joints of osteoarthritic patients. These findings suggested that
LIGHT might be involved in the progression of inflammatory bone
destruction in RA, and that osteoclast progenitors might become compe-
tent for LIGHT-mediated osteoclastogenesis via interactions with synovio-
cyte-like nurse-like cells.

Keywords: differentiation; LIGHT/TNFSF14; monocyte; osteoclast; rheu-
matoid arthritis

Introduction

Osteoclasts are large, tartrate-resistant acid phosphatase
(TRAP)-positive multinucleated cells (MNCs). Receptor
activator of nuclear factor-κB ligand (RANKL) is a key
regulator of osteoclast differentiation from haematopoietic
precursors of the monocyte/macrophage lineage.[1–3] Although
osteoclasts have an essential role in physiological bone
remodelling, increases in their number and activity,

would lead to diseases accompanied by local bone
destruction. Rheumatoid arthritis (RA) is a chronic
inflammatory disease characterized by arthritis affecting
multiple joints and the progressive destruction of cartilage
and bone.[4] Osteoclasts are important contributors to the
joint destruction in RA. Inflammatory cytokines, such as
tumour necrosis factor-α (TNF-α) and interleukin-1
(IL-1), which are upregulated in RA synovial tissues, are
known to induce the differentiation and activation of

osteoclasts.[5,6] Invasive synovial tissue at sites of bone destruction, also termed pannus, plays important roles in osteoclastic bone resorption.[7-9]

We previously established nurse-like cells (NLCs) from the synovial tissues of RA patients.[10] Although having the same appearance as fibroblast-like synoviocytes, NLCs have a number of distinct activities that could contribute to rheumatoid inflammation.[10-14] Among these are their ability to promote antibody production by B cells, the capacity to protect lymphocytes from apoptosis, and the ability to secrete large amounts of cytokines and chemokines such as IL-6 and IL-8 that could promote the accumulation and activation of lymphocytes and monocytes. However, fibroblast-like synoviocytes from patients with osteoarthritis (OA) hardly show any such activities.[10,15] Therefore, to distinguish them from general fibroblast-like synoviocytes, we have defined synovial NLCs as those that go through the active cell population from the RA synovium. The NLCs promote the survival of peripheral blood monocytes via macrophage colony-stimulating factor (M-CSF) production.[16,17] Monocytes cocultured with NLCs for 4 weeks possessed TRAP activity and differentiated into osteoclasts in response to some cytokines, including RANKL.[17] These reports have suggested that NLCs might be involved in RA-induced bone destruction by maintaining osteoclast precursors in areas of progressive synovial expansion.

LIGHT, which is homologous to lymphotoxin, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes, was recently identified as a type 2 transmembrane glycoprotein of the TNF ligand superfamily (TNFSF14).[18] LIGHT is expressed on activated T lymphocytes,[18,19] monocytes,[20] granulocytes[20] and immature dendritic cells.[21] LIGHT signalling is transduced via two members of the TNFR family, herpes virus entry mediator (HVEM, TNFRSF14) and lymphotoxin β receptor (LTβR, TNFRSF3). The HVEM is expressed prominently on monocytes, dendritic cells and lymphocytes,[19,22-24] whereas LTβR is expressed on many cell types with the exception of lymphocytes.[18,20,25] LIGHT has been shown to regulate cell proliferation[21,26,27] and apoptosis,[20,28] to induce the secretion of various cytokines, and to augment the expression of adhesion molecules.[26,29-31] Recently, Kim *et al.* reported that LIGHT was overexpressed in the synovial tissue of RA patients and that it induced the production of chemokines, cytokines and matrix metalloproteinase 9 (MMP-9) from macrophages in synovial fluid.[32] Moreover, LIGHT contributes to the survival and activation of synovial fibroblasts in RA.[33,34] These studies have suggested that LIGHT may be an important inflammatory cytokine in the development of RA. However, the roles of LIGHT in the bone destruction in RA have not yet been elucidated.

In this study, we compared the abilities to differentiate into osteoclasts in response to LIGHT, between fresh CD14$^+$ monocytes and CD14$^+$ monocytes cocultured with NLCs. We found that LIGHT induced osteoclast differentiation from CD14$^+$ monocytes cocultured with NLCs, but not from freshly isolated CD14$^+$ monocytes. Furthermore, LIGHT-induced osteoclasts express MMP-12, which was not expressed in osteoclasts induced by RANKL, and the MMP-12-expressing osteoclasts were observed at the erosive areas in the subchondral bones of RA patients, but not in those of OA patients. These findings suggest that CD14$^+$ monocytes gain the ability to differentiate into osteoclasts in response to LIGHT through their interactions with NLCs, and that LIGHT plays a critical role in the inflammatory joint destruction in RA.

Materials and methods

Cells and cultures

Nurse-like cells were established from synovial tissues obtained from RA patients, as described previously.[10] NLCs were cultured in Dulbecco's modified Eagle's minimum essential medium (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS). The NLCs from passages 4–9 were used for each experiment. Mononuclear cells were collected from the venous blood of healthy volunteers and CD14$^+$ monocytes were prepared by further separation using anti-CD14 antibody-coated beads, as described previously.[16] CD14$^+$ monocytes (2.0×10^6 cells/well) were cocultured with NLCs (2.0×10^5 cells/well) in six-well plates. Half of the medium was replaced every 3 days with fresh medium. After coculture for 4 weeks, floating or weakly adherent monocytes were harvested as NLC-supported CD14$^+$ monocytes (NCD14$^+$ monocytes) by gently washing the culture with fresh medium. Over 97% of NCD14$^+$ monocytes were TRAP positive, and their purity was confirmed cytochemically, as reported previously.[16] All human specimens were obtained with written informed consent according to the study protocol, which was approved by the review board of the Sagamihara National Hospital.

Osteoclast formation assay

In the presence of 25 ng/ml recombinant human M-CSF (R&D Systems, Minneapolis, MN), freshly isolated CD14$^+$ monocytes (1.0×10^5 cells/well) and NCD14$^+$ monocytes (2.0×10^4 cells/well) were cultured in 96-well plates in α-minimum essential medium (Invitrogen) supplemented with 10% FCS. As indicated, the cells were further stimulated with 40 ng/ml recombinant human RANKL (Peprotech, London, UK) and/or various concentrations of recombinant human LIGHT (R&D Systems). After vari-

ous periods of time, as indicated in the Results, cells were fixed and stained for TRAP using a TRAP staining kit (Wako, Osaka, Japan). Osteoclasts were identified as TRAP-positive MNCs (more than five nuclei). AlexaFluor546-conjugated phalloidin was used to stain for F-actin (Invitrogen).

Bone resorption assay

In the presence of 25 ng/ml M-CSF, NCD14$^+$ monocytes were cultured on cortical bone slices in α-minimum essential medium supplemented with 10% FCS and further stimulated with 40 ng/ml RANKL and/or 100 ng/ml LIGHT. After 21 days, the bone slices were stained with Mayer's haematoxylin solution to detect resorption pits. The concentration of the type I collagen C-telopeptide (CTX-I) in the culture supernatant was quantified using the CrossLaps for Culture kit (Nordic Biosciences Diagnostics, Herlev, Denmark), according to the manufacturer's instructions.

Quantitative polymerase chain reaction analysis

Total RNA was prepared using an RNeasy Micro kit (Qiagen, Tokyo, Japan) and complementary DNA (cDNA) was generated from the RNA using Omniscript Reverse Transcriptase (Qiagen) following the manufacturer's instructions. The cDNA was used as a template for real-time quantitative polymerase chain reaction (PCR) in a LightCycler (Roche Diagnostics, Tokyo, Japan). The PCR was performed using SYBR Premix Ex Taq (Takara, Kyoto, Japan). The PCR primers used in this study were as follows: for NFATc1, 5'-TACCAGGTGCACCGCATCA-3' and 5'-TTTCAGGATTCCGGCACAGTC-3'; for TRAP, 5'-TGCA GATCCTGGGTGCAGAC-3' and 5'-GAGTATGCAATC TGGGCAGAGACA-3'; for cathepsin K, 5'-AGCT GCAATAGCGATAATCTGAACC-3' and 5'-CGTTGTTC TTATTTCGAGCCATGA-3'; for carbonic anhydrase II, 5'-GCGACCATGTCCCATCACTG-3' and 5'-TGGCTGTAT GAGTGTCGATGTCAA-3'; for gyceraldehyde 3-phosphate dehydrogenase (GAPDH), 5'-GCACCGTCAAGGCTGAG AAC-3' and 5'-ATGGTGGTGAAGACGCCAGT-3'; for LIGHT, 5'-TCACGAGGTCAACCCAGCAG-3' and 5'-CC CAGCTGCACCTTGGAGTAG-3'; for HVEM, 5'-TTTG CTCCACAGTTGGCCTAATC-3' and 5'-CAATGACTGT GGCCTCACCTTC-3'; for LTβR, 5'-ATGCTGATGCTG-GCCGTTC-3' and 5'-AGGCTCCCAGCTTCCAGCTA-3'; for RANK, 5'-TTGTGCCGCCTAAGTGGA-3' and 5'-ACC ACCTTGATCTGGGTAGCACATA-3'; for MMP-9, 5'-AC CTCGAACTTTGACAGCGACA-3' and 5'-GATGCCATTC ACGTCGTCCTTA-3'; for MMP-12, 5'-TTGATGGCAAA GGTGGAATCCTA-3' and 5'-AGGAATGGCCAATCTCGT GAAC-3'. The PCR was performed under the following conditions: initial denaturation at 95° for 10 seconds, then 40 cycles of 95° for 5 seconds and 60° for 20

seconds. SYBR green dye was used to detect amplified products and melting curves were routinely recorded to verify the singularity of the PCR product. In each sample, the level of cDNA was normalized based on the expression level of GAPDH.

Immunohistochemical and TRAP staining of tissue samples

Affected knee joints were resected during joint replacement surgery from five RA and three OA patients who had given written informed consent. Serial sections of the decalcified and paraffin-embedded subchondral bone were dewaxed and reacted with anti-human MMP-12 monoclonal antibody (clone 4D2, R&D Systems). Sections were then reacted with anti-mouse immunoglobulin G–horse-radish peroxidase conjugate, chromogenic substrate and hydrogen peroxide. The neighbouring sections of those stained with anti-MMP-12 were subjected to staining with second antibody alone as a negative control or with TRAP staining as described above.

Statistical analysis

All data are expressed as means ± SD. A non-paired Student's t-test was used for comparison, using the STATVIEW program (Abacus Concepts, Berkeley, CA). $P < 0.05$ was considered to be statistically significant.

Results

LIGHT induces the differentiation of NCD14$^+$ monocytes into TRAP-positive MNCs

To investigate whether or not LIGHT is involved in local bone destruction, we examined the effects of LIGHT on osteoclastogenesis using established osteoclast precursors (NCD14$^+$ monocytes) in addition to freshly prepared CD14$^+$ monocytes, as described in the *Materials and methods* section.

In the presence of M-CSF, CD14$^+$ or NCD14$^+$ monocytes were cultured for 6 days with RANKL and/or LIGHT. As shown in Fig. 1(a,b), M-CSF alone did not induce TRAP-positive MNCs from either type of monocytes. CD14$^+$ monocytes were differentiated into TRAP-positive MNCs by RANKL, but not by LIGHT. The combination of RANKL and LIGHT had little effect on MNC formation. Conversely, NCD14$^+$ monocytes were strongly differentiated into TRAP-positive MNCs when treated with LIGHT. Although RANKL had only a slight effect on NCD14$^+$ monocytes, the combination with LIGHT enhanced the formation of TRAP-positive MNCs more than LIGHT alone (Fig. 1b). The LIGHT-induced formation of MNCs was time dependent (4–8 days, Fig. 1c), and dose dependent (1–100 ng/ml, data not shown). Freshly isolated

Figure 1. LIGHT induces the differentiation of NCD14+ monocytes into tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs). (a, b) In the presence of 25 ng/ml macrophage colony-stimulating factor (M-CSF; M), CD14+ or NCD14+ monocytes were cultured for 6 days with 40 ng/ml receptor activator of nuclear factor-κB ligand (RANKL; M + R), 100 ng/ml LIGHT (M + L), or 40 ng/ml RANKL plus 100 ng/ml LIGHT (M + L + R). *P < 0·01 versus M-CSF alone. #P < 0·01 versus NCD14+ monocytes stimulated with M-CSF plus LIGHT. (c) CD14+ or NCD14+ monocytes were cultured for the indicated periods in the presence of 25 ng/ml M-CSF plus 100 ng/ml LIGHT. Cultured cells were fixed and stained for TRAP. The number of TRAP-positive MNCs was counted. *P < 0·01 versus CD14+ monocytes. Representative results of at least three independent sets of similar experiments are shown as means ± SD of triplicate experiments.

CD14+ monocytes, however, did not differentiate into TRAP-positive MNCs, even after stimulation with 100 ng/ml LIGHT for 14 days (data not shown). When cultured with M-CSF for 4 weeks, CD14+ monocytes could not differentiate into TRAP-positive MNCs in the presence of RANKL or LIGHT (data not shown).

Increased HVEM messenger RNA expression in NCD14+ monocytes

Next, to clarify the reason for the difference in the efficiency of LIGHT-induced TRAP-positive MNC formation between NCD14+ and CD14+ monocytes, we analysed the messenger RNA (mRNA) expression of the LIGHT receptors, HVEM and LTβR, in both groups of monocytes. Quantitative real-time PCR analysis revealed that while the mRNA expression level of LTβR was not different between groups of monocytes, the level of HVEM mRNA was significantly higher in NCD14+ monocytes than in CD14+ monocytes (Fig. 2). Unexpectedly, the level of RANK mRNA in NCD14+ monocytes was higher than that in CD14+ monocytes (Fig. 2).

Analysis of the molecular phenotype of LIGHT-induced TRAP-positive MNCs derived from NCD14+ monocytes

Furthermore, we investigated the mRNA expression of major osteoclast markers, such as nuclear factor of activated T cells (NFATc1), TRAP, cathepsin K (CTSK) and


Figure 2. Expression of herpes virus entry mediator (HVEM), lymphotoxin β receptor (LTβR) and receptor activator of nuclear factor-κB (RANK) messenger RNA (mRNA) on CD14+ and NCD14+ monocytes. Total RNA was extracted from CD14+ and NCD14+ monocytes and the mRNA expression levels of HVEM, LTβR and RANK were analysed by quantitative real-time polymerase chain reaction. Representative results of at least three independent sets of similar experiments are shown as means ± SD of triplicate experiments. *P < 0·01 versus CD14+ monocytes.

carbonic anhydrase II (CAII), in LIGHT-induced TRAP-positive MNCs derived from NCD14+ monocytes, using quantitative real-time PCR analysis. In comparison with the control (M-CSF alone), the expression levels of all four genes were upregulated in TRAP-positive MNCs induced to differentiate by LIGHT for 6 days (Fig. 3a). The combination of LIGHT and RANKL stimulated their expression to a similar or slightly larger extent than LIGHT alone. When NCD14+ monocytes are stimulated

Figure 3. The molecular phenotype of LIGHT-induced tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) derived from NCD14$^+$ monocytes. In the presence of 25 ng/ml macrophage colony-stimulating factor (M-CSF; M), NCD14$^+$ monocytes were cultured for 6 days with 40 ng/ml receptor activator of nuclear factor-κB ligand (RANKL) (M + R), 100 ng/ml LIGHT (M + L), or both (M + L + R). The expression levels of (a) osteoclast markers and (b) LIGHT were determined by quantitative real-time polymerase chain reaction. Representative results of at least three independent sets of similar experiments are shown as means ± SD of triplicate experiments. *$P < 0.05$ and **$P < 0.01$ versus M-CSF alone.

by LIGHT or LIGHT plus RANKL, the CTSK and TRAP mRNA expression levels are higher in NCD14$^+$ monocytes stimulated for 12 days than in those stimulated for 6 days (data not shown). These inductions suggest that prolonged stimulation with LIGHT can induce more mature osteoclasts. Moreover, LIGHT induced an increase in its own expression level in NCD14$^+$ monocytes (Fig. 3b).

LIGHT-induced TRAP-positive MNCs from NCD14$^+$ monocytes have bone resorption activity

Since the expression levels of genes related to bone resorption by osteoclasts were upregulated in LIGHT-induced TRAP-positive MNCs from NCD14$^+$ monocytes, we assessed whether or not the MNCs could resorb bone. The formation of a ringed F-actin structure, called an actin ring, is closely related to osteoclast function.[35] Actin rings were recognized at the periphery of LIGHT-induced MNCs regardless of the presence of RANKL (Fig. 4a). Furthermore, resorption pits were observed on bone slices in the cultures treated with LIGHT, and the effect of LIGHT was enhanced by additional stimulation with RANKL (Fig. 4b). As expected, CTX-I release was induced in the presence of LIGHT and further increased by the

combination with RANKL (Fig. 4c). By contrast, cells treated with M-CSF alone or with a combination of M-CSF and RANKL did not form resorption pits.

LIGHT-induced TRAP-positive MNCs from NCD14$^+$ monocytes express both MMP-9 mRNA and MMP-12 mRNA

In osteoclasts, MMP-9 is abundant and it is known to be a protease involved in bone resorption. We examined MMP-9 mRNA expression in both fresh CD14$^+$ and NCD14$^+$ monocytes stimulated by LIGHT or RANKL. Compared with RANKL, LIGHT or the combination of LIGHT and RANKL enhanced MMP-9 mRNA expression in both groups of monocytes (Fig. 5a). On the other hand, because we previously reported that MMP-12 was expressed in MNCs induced from NCD14$^+$ monocytes, but not in those from CD14$^+$ monocytes,[36] the influence of LIGHT upon the expression of MMP-12 mRNA in both monocytes was investigated. NCD14$^+$ monocytes strongly upregulated MMP-12 mRNA expression in response to LIGHT or the combination of LIGHT and RANKL, compared with control (M-CSF alone) or RANKL, whereas the MMP-12 mRNA levels

Figure 4. Osteoclastic functions of LIGHT-induced tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) from NCD14$^+$ monocytes. (a) For actin ring formation, NCD14$^+$ monocytes were stimulated, in the presence of 25 ng/ml macrophage colony-stimulating factor (M-CSF), with 100 ng/ml LIGHT (M + L), or 40 ng/ml receptor activator of nuclear factor-κB ligand (RANKL) plus 100 ng/ml LIGHT (M + L + R) for 6 days. Fixed cells were stained with Alexa-Fluor546-conjugated phalloidin. (b) In the presence of 25 ng/ml M-CSF (M), NCD14$^+$ monocytes were cultured for 21 days on bone slices with 40 ng/ml RANKL (M + R), 100 ng/ml LIGHT (M + L), or both (M + L + R). (c) The release of type I collagen C-telopeptide (CTX-I) was quantified in the culture supernatants using enzyme-linked immunosorbent assay. Representative results of at least three independent sets of similar experiments are shown as means ± SD of triplicate experiments. $^*P < 0.05$ and $^{**}P < 0.01$ versus M-CSF alone.

remained low in CD14$^+$ monocytes after any stimulation (Fig. 5b).

Detection of TRAP-positive MNCs expressing MMP-12 in the subchondral bone of RA patients

To confirm the presence of MMP-12-expressing MNCs in the erosive area of the RA joint, serial sections of decalcified, paraffin-embedded subchondral bone of five RA patients and three OA patients were subjected to immunostaining with an anti-MMP-12 antibody. As shown in Fig. 6(a,b), both MMP-12-positive and MMP-12-negative MNCs expressing TRAP were present in the affected bone areas of all five RA patients examined in this study. The ratios of MMP-12-positive MNCs to TRAP-positive MNCs in RA patients were 46·7% (30/63) in patient 1, 52·5% (31/59) in patient 2, 41·7% (33/79) in patient 3, 2·2% (3/135) in patient 4, and 10·0% (9/90) in patient 5. By contrast, no MMP-12-positive MNCs were observed in the OA patients (Fig. 6b).

Discussion

Formation of osteoclasts and consequent joint destruction are hallmarks of RA. We previously reported that CD14$^+$ monocytes cocultured with NLCs (termed NCD14$^+$ monocytes in this article) were TRAP positive and that NCD14$^+$ monocytes differentiated into osteoclasts following treatment with RANKL or TNF-α. Consequently, NCD14$^+$ monocytes have been thought to be osteoclast precursors.[16,17]

In this study, to investigate whether LIGHT is involved in bone destruction in RA, we examined the effects of LIGHT on osteoclastogenesis using CD14$^+$ and NCD14$^+$ monocytes, and compared their abilities to differentiate into osteoclasts. When stimulated with RANKL for 6 days, a number of TRAP-positive MNCs, mature osteoclasts, were generated from CD14$^+$ monocytes, but only a few MNCs were generated from NCD14$^+$ monocytes. Conversely, LIGHT strongly induced MNCs from NCD14$^+$ monocytes, but not from CD14$^+$ monocytes.

Figure 5. Comparison of matrix metalloproteinase-9 (MMP-9) and MMP-12 messenger RNA (mRNA) expression in CD14$^+$ or NCD14$^+$ monocyte-derived tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs). In the presence of 25 ng/ml macrophage-colony-stimulating factor (M-CSF; M), CD14$^+$ or NCD14$^+$ monocytes were cultured for 6 days with 40 ng/ml receptor activator of nuclear factor-κB ligand (RANKL; M + R), 100 ng/ml LIGHT (M + L), or both (M + L + R). The mRNA expression levels of (a) MMP-9 and (b) MMP-12 were determined by quantitative real-time polymerase chain reaction. Representative results of at least three independent sets of similar experiments are shown as means ± SD of triplicate experiments. *$P < 0.05$ and **$P < 0.01$ versus M-CSF alone.

Furthermore, LIGHT-induced MNCs derived from NCD14$^+$ monocytes showed several characteristics of osteoclasts, including the expression of genes encoding NFATc1, TRAP, CTSK and CAII, actin-ring formation, and the ability to resorb bone. These results indicate that LIGHT might be involved in bone destruction by forming osteoclasts from precursors through the interaction with NLCs.

RANKL enhanced LIGHT-induced osteoclast formation and bone resorption. Recent reports have shown that synoviocytes from patients with RA express a higher level of RANKL and could induce osteoclastogenesis from synovial macrophages.[7-9] Hence, the synergistic effects of RANKL and LIGHT on osteoclastogenesis may play an important role in the bone destruction in RA. LIGHT has

been reported to be augmented in RA synovial fluids compared with those in OA patients.[34] Reports on the LIGHT-expressing cells in RA synovial tissue remain confused because of inconsistent immunohistochemical evaluations. These cells have been separately identified as macrophages[32] and T lymphocytes.[34] In the present study, LIGHT induced its own expression in NCD14$^+$ monocytes, suggesting that LIGHT might drive a positive feedback loop of osteoclastogenesis. LIGHT induced the expression of intercellular adhesion molecule-1 (ICAM-1) in RA synovial fibroblasts,[33,34] and the expression of IL-8 and monocyte chemoattractant protein-1 in RA synovial macrophages.[32] Since ICAM-1 and these chemokines could play a crucial role in the recruitment of monocytes into the synovial sublining,[37] LIGHT might not only induce osteoclastogenesis, but also increase the number of osteoclast precursors in the synovium of RA patients by recruiting monocytes. The exact mechanism by which NCD14$^+$ monocytes gain the ability to differentiate into osteoclasts in response to LIGHT is unclear. In this study, we confirmed the upregulation of HVEM only at the mRNA level. If HVEM mRNA expression correlates with protein expression, augmented HVEM can explain how the cells gain the ability to differentiate into osteoclasts in response to LIGHT. On the other hand, the decreasing responsiveness of NCD14$^+$ monocytes to RANKL alone contradicts the increasing expression of RANK mRNA. Because RANKL drastically enhanced LIGHT-induced osteoclastogenesis from NCD14$^+$ monocytes and the bone-resorbing activity, NCD14$^+$ cells could be responsive to RANKL. These findings indicate that the decreasing responsiveness to RANKL may be the result of alterations in the downstream pathways of RANK/RANKL signalling in NCD14$^+$ monocytes. Whereas LIGHT could not induce osteoclast differentiation from CD14$^+$ monocytes, it has been previously reported that LIGHT induces the expression of MMP-9 in monocytes.[31,32,38] These findings suggest that CD14$^+$ monocytes could somehow respond to LIGHT via HVEM or LTβR.

A recent study reported that LIGHT promotes osteoclastogenesis in RANKL-dependent and -independent manners;[39] however, in the present study, we could not observe LIGHT-induced osteoclastogenesis from CD14$^+$ monocytes. The discrepancy might be caused by differences in culture conditions or in the monocyte preparation methods (an adherence technique versus a magnetic bead method).

In addition to MMP-9 expression, LIGHT-induced MNCs derived from NCD14$^+$ monocytes expressed MMP-12 mRNA, which was not expressed in osteoclasts induced from CD14$^+$ monocytes by RANKL. The TRAP-positive MNCs expressing MMP-12 were present in the erosive areas of RA joints, but were not found in the affected bones of OA joints, implying that they may be unique to RA.

Figure 6. Detection of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) expressing matrix metalloproteinase-12 (MMP-12) in the erosive area of the rheumatoid arthritis (RA) joint. Affected subchondral bone samples were obtained from the resected knee joints of patients with RA and patients with osteoarthritis (OA). Serial sections were cut from decalcified and paraffin-embedded subchondral bone. (a) RA tissue samples were stained with anti-human MMP-12 monoclonal antibody. Neighbouring sections were stained for TRAP activity (b) or with second antibody alone as a negative control (c). All three sections were consecutive. (d) RA and (e) OA tissue samples were stained with anti-human MMP-12 monoclonal antibody. Solid arrowheads and open arrowheads show MMP-12-positive and -negative MNCs, respectively. Representative results from five RA patients and three OA patients are shown.

Although MMP-12 was expressed in rabbit and mouse osteoclasts,[40] MMP-12-expressing osteoclasts have not been identified in humans. This is the first report to demonstrate the presence of MMP-12-expressing osteoclasts in human RA joints. Increased expression of MMP-12 in RA synovial tissues and synovial fluids indicates the involvement of this enzyme in RA pathogenesis.[41] A study using MMP-12-deficient mice demonstrated that MMP-12 was not critical for bone resorption or osteoclast recruitment.[40] Although MMP-12 might not be directly involved in bone resorption in humans, several reports suggest that MMP-12 could be involved in cartilage destruction.[42,43] We previously reported that NCD14[+] and MMP-12-producing osteoclast-like cells differentiated from NCD14[+] monocytes could degrade the proteoglycan of bovine cartilage.[36] MMP-12 is critical for invasion and destruction in pathologies such as emphysema[44] and cutaneous granulomas.[45] Rheumatoid arthritis is also a granulomatous disease with tissue hyperplasia and destruction. Osteoclasts invading uncalcified cartilage beyond the tidemark are frequently found in the erosive areas of RA joints. Consequently, MMP-12-producing osteoclasts might play important roles in inflammation or cartilage destruction as well as in the bone destruction in RA.

Synovial fluid macrophages from RA patients could differentiate into osteoclasts via both RANKL and TNF-α signalling pathways, whereas OA macrophages differentiated into osteoclasts only through the RANKL pathway.[46] Moreover, osteoclasts derived from circulating precursors in RA patients have an increased bone-resorbing activity.[47] Osteoclast precursors responsive to inflammatory cytokines such as LIGHT would be present in RA patients, and the cytokine-induced osteoclastogenesis might be involved in enhanced bone destruction in RA. Although it should become clear from further investigations whether or not LIGHT-induced MNCs are identical to the MMP-12-expressing osteoclasts of RA joints, our in vitro differentiation system is robust and reproducible. All monocytes become LIGHT-responsive precursors of osteoclast-like cells via their interactions with RA-NLCs. We believe that our coculture system should be useful for elucidating the interactions between synovial cells and infiltrating monocytes in the pathogenic condition of RA, and the mechanism underlying inflammation-associated osteoclastogenesis.

The present study strongly suggested that LIGHT might be involved in the progression of bone destruction in RA, and implied that the blocking of LIGHT signalling may be a therapeutic target for the enhanced bone destruction in RA.

Disclosures

The authors have no financial conflict of interest.

Acknowledgements

References

1 Kong YY, Yoshida H, Sarosi I *et al.* OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* 1999; 397:315–23.

2 Yasuda H, Shima N, Nakagawa N *et al.* Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci U S A* 1998; 95:3597–602.

3 Lacey DL, Timms E, Tan HL *et al.* Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998; 93:165–76.

4 Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. *Arthritis Rheum* 2000; 43:2619–33.

5 Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. *J Pathol* 2002; 198:220–7.

6 Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. *J Clin Invest* 2005; 115:282–90.

7 Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. *Arthritis Rheum* 2000; 43:250–8.

8 Takayanagi H, Iizuka H, Juji T *et al.* Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. *Arthritis Rheum* 2000; 43:259–69.

9 Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. *Arthritis Rheum* 2000; 43:2523–30.

10 Takeuchi E, Tomita T, Toyosaki-Maeda T *et al.* Establishment and characterization of nurse cell-like stromal cell lines from synovial tissues of patients with rheumatoid arthritis. *Arthritis Rheum* 1999; 42:221–8.

11 Shimaoka Y, Attrep JF, Hirano T, Ishihara K, Suzuki R, Toyosaki T, Ochi T, Lipsky PE. Nurse-like cells from bone marrow and synovium of patients with rheumatoid arthritis promote survival and enhance function of human B cells. *J Clin Invest* 1998; 102:606–18.

12 Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. *J Clin Invest* 2001; 107:305–15.

13 Tanaka K, Mori T, Juji T *et al.* Production of interleukin-6 and interleukin-8 by nurse-like cells from rheumatoid arthritis patients after stimulation with monocytes. *Mod Rheumatol* 2005; 15:415–22.

14 Ochi T, Yoshikawa H, Toyosaki-Maeda T, Lipsky PE. Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis. *Arthritis Res Ther* 2007; 9:201.

15 Takano H, Tomita T, Toyosaki-Maeda T *et al.* Comparison of the activities of multinucleated bone-resorbing giant cells derived from CD14-positive cells in the synovial fluids of rheumatoid arthritis and osteoarthritis patients. *Rheumatology (Oxford)* 2004; 43:435–41.

16 Toyosaki-Maeda T, Takano H, Tomita T *et al.* Differentiation of monocytes into multinucleated giant bone-resorbing cells: two-step differentiation induced by nurse-like cells and cytokines. *Arthritis Res* 2001; 3:306–10.

17 Tsuboi H, Udagawa N, Hashimoto J, Yoshikawa H, Takahashi N, Ochi T. Nurse-like cells from patients with rheumatoid arthritis support the survival of osteoclast precursors via macrophage colony-stimulating factor production. *Arthritis Rheum* 2005; 52:3819–28.

18 Mauri DN, Ebner R, Montgomery RI *et al.* LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. *Immunity* 1998; 8:21–30.

19 Morel Y, Schiano de Colella JM, Harrop J *et al.* Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. *J Immunol* 2000; 165:4397–404.

20 Zhai Y, Guo R, Hsu TL *et al.* LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses *in vivo* tumor formation via gene transfer. *J Clin Invest* 1998; 102:1142–51.

21 Tamada K, Shimozaki K, Chapoval AI *et al.* LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. *J Immunol* 2000; 164:4105–10.

22 Kwon BS, Tan KB, Ni J *et al.* A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. *J Biol Chem* 1997; 272:14272–6.

23 Zou GM, Hu WY. LIGHT regulates CD86 expression on dendritic cells through NF-kappaB, but not JNK/AP-1 signal transduction pathway. *J Cell Physiol* 2005; 205:437–43.

24 Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. *J Biol Chem* 1997; 272:14029–32.

25 Force WR, Walter BN, Hession C, Tizard R, Kozak CA, Browning JL, Ware CF. Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. *J Immunol* 1995; 155:5280–8.

26 Harrop JA, McDonnell PC, Brigham-Burke M *et al.* Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. *J Biol Chem* 1998; 273:27548–56.

27 Wei CY, Chou YH, Ho FM, Hsieh SL, Lin WW. Signaling pathways of LIGHT induced macrophage migration and vascular smooth muscle cell proliferation. *J Cell Physiol* 2006; 209:735–43.

28 Wang J, Lo JC, Foster A *et al.* The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. *J Clin Invest* 2001; 108:1771–80.

29 Scholz H, Sandberg W, Damas JK *et al.* Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. *Circulation* 2005; 112:2121–9.

30 Chang YH, Hsieh SL, Chao Y, Chou YC, Lin WW. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells. *J Biomed Sci* 2005; 12:363–75.

31 Otterdal K, Smith C, Oie E *et al.* Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. *Blood* 2006; 108:928–35.

32 Kim WJ, Kang YJ, Koh EM, Ahn KS, Cha HS, Lee WH. LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of pro-inflammatory cytokines and MMP-9 in macrophages. *Immunology* 2005; 114:272–9.

33 Kang YM, Kim SY, Kang JH, Han SW, Nam EJ, Kyung HS, Park JY, Kim IS. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. *Arthritis Rheum* 2007; 56:1106–17.

34 Pierer M, Brentano F, Rethage J, Wagner U, Hantzschel H, Gay RE, Gay S, Kyburz D. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. *Rheumatology (Oxford)* 2007; 46:1063–70.

35 Nakamura I, Takahashi N, Sasaki T, Jimi E, Kurokawa T, Suda T. Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. *J Bone Miner Res* 1996; 11:1873–9.

36 Tsuboi H, Matsui Y, Hayashida K *et al.* Tartrate resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage. *Ann Rheum Dis* 2003; 62:196–203.

37 Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. *Arthritis Res* 2001; 3:118–26.

38 Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, Kwon BS, Park JE. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. *Arterioscler Thromb Vasc Biol* 2001; 21:2004–10.

39 Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, Sabokbar A. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. *Arthritis Rheum* 2006; 54:1451–62.

40 Hou P, Troen T, Ovejero MC *et al.* Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. *Bone* 2004; 34:37–47.

41 Liu M, Sun H, Wang X *et al.* Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. *Arthritis Rheum* 2004; 50:3112–7.

42 Wang X, Liang J, Koike T *et al.* Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. *Am J Pathol* 2004; 165:1375–83.

43 Janusz MJ, Hare M, Durham SL, Potempa J, McGraw W, Pike R, Travis J, Shapiro SD. Cartilage proteoglycan degradation by a mouse transformed macrophage cell line is mediated by macrophage metalloelastase. *Inflamm Res* 1999; 48:280–8.

44 Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. *Science* 1997; 277:2002–4.

45 Vaalamo M, Kariniemi AL, Shapiro SD, Saarialho-Kere U. Enhanced expression of human metalloelastase (MMP-12) in cutaneous granulomas and macrophage migration. *J Invest Dermatol* 1999; 112:499–505.

46 Adamopoulos IE, Sabokbar A, Wordsworth BP, Carr A, Ferguson DJ, Athanasou NA. Synovial fluid macrophages are capable of osteoclast formation and resorption. *J Pathol* 2006; 208:35–43.

47 Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. *Rheumatology (Oxford)* 2002; 41:1232–9.